Evidence map›Paper›PMID 38561602›Full record

Trial reportAddiction (Abingdon, England)2024

Integrated care van delivery of evidence-based services for people who inject drugs: A cluster-randomized trial.

Kathleen R Page, Brian W Weir, Katie Zook, Amanda Rosecrans, Robert Harris, Suzanne M Grieb, Oluwaseun Falade-Nwulia, Miles Landry, Wendy Escobar, Michael P Ramirez and 4 more

Abstract readRandomized Controlled Trial
In one paragraph

Trial report in Addiction (Abingdon, England), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Review
  2. Article
  3. Mobile addiction treatment units: a narrative review.Addiction science & clinical practice · 2025
    Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Observational
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Kathleen R PageJohns Hopkins University School of Medicine, Baltimore, MD, USA.
Brian W WeirJohns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
Katie ZookJohns Hopkins University School of Medicine, Baltimore, MD, USA.
Amanda RosecransJohns Hopkins University School of Medicine, Baltimore, MD, USA.
Robert HarrisJohns Hopkins University School of Medicine, Baltimore, MD, USA.
Suzanne M GriebJohns Hopkins University School of Medicine, Baltimore, MD, USA.
Oluwaseun Falade-NwuliaJohns Hopkins University School of Medicine, Baltimore, MD, USA.
Miles LandryJohns Hopkins University School of Medicine, Baltimore, MD, USA.
Wendy EscobarJohns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
Michael P RamirezJohns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
Ronald E SaxtonJohns Hopkins University School of Medicine, Baltimore, MD, USA.
William A ClarkeJohns Hopkins University School of Medicine, Baltimore, MD, USA.
Susan G ShermanJohns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
Gregory M LucasJohns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID 0000-0002-3013-4339

Funding

Vaccine Response and Immunotherapeutics SWGP30AI094189 · NIAID · JOHNS HOPKINS UNIVERSITY · PI Anna Palmer Durbin · 2012 to 2026
$67.0M
Juntos (Together): A community led approach to enhance to Covid-19 testing among vulnerable LatinosR01DA045556 · NIDA · JOHNS HOPKINS UNIVERSITY · PI LUCAS, GREGORY M, PAGE, KATHLEEN R · 2017 to 2022
$6.8M
Treatment outcomes and comorbidity in HIV-infected IDUK24DA035684 · NIDA · JOHNS HOPKINS UNIVERSITY · PI LUCAS, GREGORY M · 2014 to 2024
$1.5M
Mentoring in Community-engaged Research to Promote Outcomes for LatinosK24NR020508 · NINR · JOHNS HOPKINS UNIVERSITY · PI Kathleen R Page · 2022 to 2026
$942k
NIAID NIH HHS P30 AI094189NIDA NIH HHS K24 DA035684NIDA NIH HHS K24DA035684NIDA NIH HHS R01 DA045556NIDA NIH HHS R01DA045556NINR NIH HHS K24 NR020508The Johns Hopkins University Center for AIDS Research P30AI094189
6 · The paper itself

Abstract

BACKGROUND AND

aimsPeople who inject drugs (PWID) are at risk for adverse outcomes across multiple dimensions. While evidence-based interventions are available, services are often fragmented and difficult to access. We measured the effectiveness of an integrated care van (ICV) that offered services for PWID. DESIGN, SETTING AND

participantsThis was a cluster-randomized trial, which took place in Baltimore, MD, USA. Prior to randomization, we used a research van to recruit PWID cohorts from 12 Baltimore neighborhoods (sites), currently served by the city's mobile needle exchange program. INTERVENTION AND COMPARATOR: We randomized sites to receive weekly visits from the ICV (n = 6) or to usual services (n = 6) for 14 months. The ICV offered case management; buprenorphine/naloxone; screening for HIV, hepatitis C virus and sexually transmitted infections; HIV pre-exposure prophylaxis; and wound care. MEASUREMENTS: The primary outcome was a composite harm mitigation score that captured access to evidence-based services, risk behaviors and adverse health events (range = 0-15, with higher numbers indicating worse status). We evaluated effectiveness by comparing changes in the composite score at 7 months versus baseline in the two study arms.

findingsWe enrolled 720 cohort participants across the study sites (60 per site) between June 2018 and August 2019: 38.3% women, 72.6% black and 85.1% urine drug test positive for fentanyl. Over a median of 10.4 months, the ICV provided services to 734 unique clients (who may or may not have been cohort participants) across the six intervention sites, including HIV/hepatitis C virus testing in 577 (78.6%) and buprenorphine/naloxone initiation in 540 (74%). However, only 52 (7.2%) of cohort participants received services on the ICV. The average composite score decreased at 7 months relative to baseline, with no significant difference in the change between ICV and usual services (difference in differences: -0.31; 95% confidence interval: -0.70, 0.08; P = 0.13).

conclusionsThis cluster-randomized trial in Baltimore, MD, USA, found no evidence that weekly neighborhood visits from a mobile health van providing injection-drug-focused services improved access to services and outcomes among people who injected drugs in the neighborhood, relative to usual services. The van successfully served large numbers of clients but unexpectedly low use of the van by cohort participants limited the ability to detect meaningful differences.

Indexed as

Needle-Exchange ProgramsSubstance Abuse, IntravenousAdultBaltimoreBuprenorphine, Naloxone Drug CombinationDelivery of Health Care, IntegratedEvidence-Based PracticeFemaleHarm ReductionHepatitis CHIV InfectionsHumansMaleMiddle AgedMobile Health UnitsNarcotic AntagonistsBuprenorphine, Naloxone Drug CombinationNarcotic AntagonistsBuprenorphineharm reductionHCVHIVopioid use disorderpeople who inject drugsservice delivery

Identifiers

PMID38561602
PMCPMC11259310

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.